- Home
- INR vs IOVA Comparison
INR vs IOVA Comparison
Compare INR & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INR
- IOVA
- Stock Information
- Founded
- INR 2017
- IOVA 2007
- Country
- INR United States
- IOVA United States
- Employees
- INR N/A
- IOVA N/A
- Industry
- INR
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INR
- IOVA Health Care
- Exchange
- INR NYSE
- IOVA Nasdaq
- Market Cap
- INR N/A
- IOVA 1.0B
- IPO Year
- INR 2025
- IOVA N/A
- Fundamental
- Price
- INR $17.11
- IOVA $1.69
- Analyst Decision
- INR Strong Buy
- IOVA Strong Buy
- Analyst Count
- INR 7
- IOVA 9
- Target Price
- INR $27.43
- IOVA $18.22
- AVG Volume (30 Days)
- INR 229.8K
- IOVA 9.3M
- Earning Date
- INR 01-01-0001
- IOVA 05-08-2025
- Dividend Yield
- INR N/A
- IOVA N/A
- EPS Growth
- INR N/A
- IOVA N/A
- EPS
- INR N/A
- IOVA N/A
- Revenue
- INR $259,022,000.00
- IOVA $164,070,000.00
- Revenue This Year
- INR $49.25
- IOVA $182.20
- Revenue Next Year
- INR $17.14
- IOVA $62.10
- P/E Ratio
- INR $21.32
- IOVA N/A
- Revenue Growth
- INR 60.16
- IOVA 13698.99
- 52 Week Low
- INR $13.64
- IOVA $2.70
- 52 Week High
- INR $23.00
- IOVA $13.60
- Technical
- Relative Strength Index (RSI)
- INR N/A
- IOVA 24.56
- Support Level
- INR N/A
- IOVA $3.02
- Resistance Level
- INR N/A
- IOVA $3.31
- Average True Range (ATR)
- INR 0.00
- IOVA 0.24
- MACD
- INR 0.00
- IOVA -0.08
- Stochastic Oscillator
- INR 0.00
- IOVA 6.00
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.